77 related articles for article (PubMed ID: 3501427)
1. Solution conformation of carboxy-terminal fragments of the third component of human complement C3: proton nuclear magnetic resonance study of C3a, des-Arg-C3a, and C3a Arg69.
Muto Y; Fukumoto Y; Arata Y
J Biochem; 1987 Sep; 102(3):635-41. PubMed ID: 3501427
[TBL] [Abstract][Full Text] [Related]
2. Proton nuclear magnetic resonance study of the third component of complement: solution conformation of the carboxyl-terminal segment of C3a fragment.
Muto Y; Fukumoto Y; Arata Y
Biochemistry; 1985 Nov; 24(23):6659-65. PubMed ID: 3878728
[TBL] [Abstract][Full Text] [Related]
3. Proton nuclear magnetic resonance study of the solution conformation of C3a-Arg69, a 69-residue N-terminal fragment of the third component of complement.
Muto Y; Inagaki F; Arata Y
J Biochem; 1989 Feb; 105(2):330-7. PubMed ID: 2656667
[TBL] [Abstract][Full Text] [Related]
4. Conformational analysis of COOH-terminal segments of human C3a. Evidence of ordered conformation in an active 21-residue peptide.
Lu ZX; Fok KF; Erickson BW; Hugli TE
J Biol Chem; 1984 Jun; 259(12):7367-70. PubMed ID: 6610676
[TBL] [Abstract][Full Text] [Related]
5. 1H NMR studies of human C3a anaphylatoxin in solution: sequential resonance assignments, secondary structure, and global fold.
Chazin WJ; Hugli TE; Wright PE
Biochemistry; 1988 Dec; 27(26):9139-48. PubMed ID: 3266557
[TBL] [Abstract][Full Text] [Related]
6. Helical conformation at the carboxy-terminal portion of human C3a is required for full activity.
Hoeprich PD; Hugli TE
Biochemistry; 1986 Apr; 25(8):1945-50. PubMed ID: 3486674
[TBL] [Abstract][Full Text] [Related]
7. Secondary structure of complement component C3a anaphylatoxin in solution as determined by NMR spectroscopy: differences between crystal and solution conformations.
Nettesheim DG; Edalji RP; Mollison KW; Greer J; Zuiderweg ER
Proc Natl Acad Sci U S A; 1988 Jul; 85(14):5036-40. PubMed ID: 3260670
[TBL] [Abstract][Full Text] [Related]
8. Human anaphylatoxin (C3a) from the third component of complement. Primary structure.
Hugli TE
J Biol Chem; 1975 Nov; 250(21):8293-301. PubMed ID: 1238393
[TBL] [Abstract][Full Text] [Related]
9. The secreted Candida albicans protein Pra1 disrupts host defense by broadly targeting and blocking complement C3 and C3 activation fragments.
Luo S; Dasari P; Reiher N; Hartmann A; Jacksch S; Wende E; Barz D; Niemiec MJ; Jacobsen I; Beyersdorf N; Hünig T; Klos A; Skerka C; Zipfel PF
Mol Immunol; 2018 Jan; 93():266-277. PubMed ID: 28860090
[TBL] [Abstract][Full Text] [Related]
10. The primary structure of porcine C3a anaphylatoxin.
Corbin NC; Hugli TE
J Immunol; 1976 Sep; 117(3):990-5. PubMed ID: 956663
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of in vitro natural killer activity by the third component of complement: role for the C3a fragment.
Charriaut C; Senik A; Kolb JP; Barel M; Frade R
Proc Natl Acad Sci U S A; 1982 Oct; 79(19):6003-7. PubMed ID: 6985269
[TBL] [Abstract][Full Text] [Related]
12. Anaphylatoxin-mediated regulation of the immune response. I. C3a-mediated suppression of human and murine humoral immune responses.
Morgan EL; Weigle WO; Hugli TE
J Exp Med; 1982 May; 155(5):1412-26. PubMed ID: 6978374
[TBL] [Abstract][Full Text] [Related]
13. Human platelet activation by C3a and C3a des-arg.
Polley MJ; Nachman RL
J Exp Med; 1983 Aug; 158(2):603-15. PubMed ID: 6604123
[TBL] [Abstract][Full Text] [Related]
14. A proton nuclear magnetic resonance study of the conformation of bovine anaphylatoxin C5a in solution.
Zarbock J; Gennaro R; Romeo D; Clore GM; Gronenborn AM
FEBS Lett; 1988 Oct; 238(2):289-94. PubMed ID: 3262536
[TBL] [Abstract][Full Text] [Related]
15. Factor C3f is a spasmogenic fragment released from C3b by factors I and H: the heptadeca-peptide C3f was synthesized and characterized.
Ganu VS; Müller-Eberhard HJ; Hugli TE
Mol Immunol; 1989 Oct; 26(10):939-48. PubMed ID: 2531841
[TBL] [Abstract][Full Text] [Related]
16. Tertiary structure of human complement component C5a in solution from nuclear magnetic resonance data.
Zuiderweg ER; Nettesheim DG; Mollison KW; Carter GW
Biochemistry; 1989 Jan; 28(1):172-85. PubMed ID: 2784981
[TBL] [Abstract][Full Text] [Related]
17. Synthetic peptides with the biological activities and specificity of human C3a anaphylatoxin.
Hugli TE; Erickson BW
Proc Natl Acad Sci U S A; 1977 May; 74(5):1826-30. PubMed ID: 266705
[TBL] [Abstract][Full Text] [Related]
18. Generation, purification and functional characterization of three C3a anaphylatoxins in rainbow trout: role in leukocyte chemotaxis and respiratory burst.
Rotllant J; Parra D; Peters R; Boshra H; Sunyer JO
Dev Comp Immunol; 2004 Jun; 28(7-8):815-28. PubMed ID: 15043949
[TBL] [Abstract][Full Text] [Related]
19. Purification and partial characterization of human and porcine C3a anaphylatoxin.
Hugli TE; Vallota EH; Müller-Eberhard HJ
J Biol Chem; 1975 Feb; 250(4):1472-8. PubMed ID: 803505
[TBL] [Abstract][Full Text] [Related]
20. [Atopic dermatitis. II. The status of complement proteins and the pathogenetic role of anaphylatoxins C4a, C3a and C5a].
Sergeev IuV; Reznikov IuP; Lobanova EV; Pimenova NS
Vestn Dermatol Venerol; 1989; (4):4-7. PubMed ID: 2788339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
